Oncology Reports 2000-01-01

Interferon alpha-2b at low doses as long-term antiangiogenic treatment of a metastatic intracranial hemangioendothelioma: a case report.

G Palmieri, L Montella, A Martignetti, A R Bianco

Index: Oncol. Rep. 7(1) , 145-9, (2000)

Full Text: HTML

Abstract

We describe a case of intracranial haemangioendothelioma in a 20-year old female patient who presented severe neurological symptoms and relapsed after two surgical interventions. The patient was treated with low doses of recombinant interferon alpha-2b (1 MUI three times a week) after surgical resection which led to recovery of daily function and work activity. To our knowledge, this is the ninth patient reported with intracranial hemangioendothelioma, but the only one having diffuse and painful bone metastases resolved by treatment with interferon. After 30 months the patient is free from symptoms and recurrence. The effectiveness shown by recombinant interferon alpha-2b against vascular neoplasms prompted us to look for the possible biological basis of such a property.

Related Compounds

  • interferon alfa-2b

Related Articles:

Topical chemotherapy for ocular surface squamous neoplasia.

2013-07-01

[Curr. Opin. Ophthalmol. 24(4) , 336-42, (2013)]

Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

2004-03-01

[Leuk. Res. 28(3) , 249-57, (2004)]

Studies on the expression and processing of human proinsulin derivatives encoded by different DNA constructs.

2013-10-01

[Biochim. Biophys. Acta 1834(10) , 2116-23, (2013)]

Conjunctival papilloma: features and outcomes based on age at initial examination.

2013-05-01

[JAMA Ophthalmol. 131(5) , 585-93, (2013)]

[Systemic mastocytosis--new therapeutic strategies].

2013-01-09

[Rev. Med. Suisse 9(368) , 17-21, (2013)]

More Articles...